Ntagirabiri Rénovat, Poveda Jean Dominique, Mumana Annie, Ndayishimiye Hermelance
Centre des Maladies Digestives et du Foie « CEMADIF », Bujumbura, Burundi.
Laboratoire Cerba, Paris, France.
Pan Afr Med J. 2014 Sep 24;19:69. doi: 10.11604/pamj.2014.19.69.4580. eCollection 2014.
Hepatitis C virus (HCV) infection is a major public health issue. HCV genotype identification is clinically important to tailor the dosage and duration of treatment. Indeed, distinct therapeutic approaches are required for each genotype. Up to now, there is no study assessing HCV genotypes and subtypes in Burundi. The aim of the study was to determine HCV genotypes and subtypes in Burundi and to highlight the difficulties related to LiPA Method, widely used for African samples.
In this study, a total of 179 samples contained anti-HCV antibodies were tested for HCV RNA, genotyping and subtyping. The analysis had been made in Cerba laboratory, Paris, France.
166 patients (92.7%) were genotype 4; 10 patients (5.6%) were genotype 1 and 3 patients (1.7%) were genotype 3. It was possible to determine subtypes for 51 HCV-4 (30.7%) patients. Among these, 25 (49.1%) had 4h subtype; 11 (21.6%) had 4e subtype; 2 (3.9%) had 4k subtype and 13 patients (25.5%) had 4a/4c/4d subtype. The LiPA method failed to subtype 115 (69.3%) HCV-4 and to separate the three subtype: 4a, 4c and 4d.
Genotype 4 and subtype 4h followed by 4e are the widespread in Burundi.
丙型肝炎病毒（HCV）感染是一个重大的公共卫生问题。HCV基因型鉴定对于确定治疗剂量和疗程具有重要临床意义。事实上，每种基因型都需要不同的治疗方法。到目前为止，尚无关于布隆迪HCV基因型和亚型的研究。本研究的目的是确定布隆迪的HCV基因型和亚型，并强调广泛用于非洲样本的线性探针分析（LiPA）方法存在的困难。
本研究共检测了179份抗HCV抗体阳性样本的HCV RNA、基因分型和亚型分析。分析在法国巴黎的塞尔巴实验室进行。
166例患者（92.7%）为4型基因型；10例患者（5.6%）为1型基因型，3例患者（1.7%）为3型基因型。51例HCV-4型（30.7%）患者的亚型可以确定。其中，25例（49.1%）为4h亚型；11例（21.6%）为4e亚型；2例（3.9%）为4k亚型，13例患者（25.5%）为4a/4c/4d亚型。LiPA方法未能对115例（69.3%）HCV-4型进行亚型分型，也未能区分4a、4c和4d这三种亚型。
4型基因型及4h亚型（其次是4e亚型）在布隆迪最为常见。
